Linking Placental Ischemia and Hypertension in Preeclampsia Role of Endothelin 1

Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216, USA.
Hypertension (Impact Factor: 6.48). 05/2012; 60(2):507-11. DOI: 10.1161/HYPERTENSIONAHA.112.194845
Source: PubMed
Download full-text


Available from: Eric M George, Aug 21, 2014
  • Source

    Hypertension 09/2009; 54(2):373-4. DOI:10.1161/HYPERTENSIONAHA.109.136424 · 6.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis inhibition by blocking vascular endothelial growth factor (VEGF)-mediated signalling with monoclonal antibodies or tyrosine kinase inhibitors has become an established treatment of various forms of cancer. This treatment is frequently associated with the development of hypertension and proteinuria. As VEGF increases the expression and the activity of nitric oxide synthase in endothelial cells, a decrease in the bioavailability of nitric oxide has been proposed as a key mechanism leading to hypertension during angiogenesis inhibition. However, results of clinical and experimental studies exploring this possibility are conflicting. Rarefaction, that is a structural decrease of microcirculatory vessels, has been reported during antiangiogenic treatment, but evidence that it plays a role in development of hypertension is lacking. Elevated circulating and urinary levels of endothelin-1 have been observed in clinical and experimental studies with angiogenesis inhibitors. Furthermore, the observation that endothelin receptor blockers can prevent or revert the rise in blood pressure during angiogenesis inhibition and attenuate proteinuria provides strong evidence that an activated endothelin-signalling pathway is a final common mediator of angiogenesis inhibition-induced rise in blood pressure and renal toxicity.
    Journal of Hypertension 12/2012; 31(3). DOI:10.1097/HJH.0b013e32835c1d1b · 4.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Administration of dexamethasone to HELLP syndrome patients (10mg i.v. every 12hours) shortens disease course and reduces maternal morbidity, in patients treated at the University of Mississippi Medical Center (UMMC), associated with this severe form of preeclampsia. However, the pathophysiologic mechanisms involved with this intervention remain unclear. OBJECTIVE: We sought to investigate the potential role of i.v. dexamethasone to restore the imbalance among anti-angiogenic and inflammatory factors known to be significantly elevated in women with HELLP syndrome. STUDY DESIGN: Single center prospective study of women diagnosed with HELLP syndrome that were treated for i.v. dexamethasone at UMMC. Blood was drawn prior to dexamethasone administration and again 12 and 24hrs post initial dexamethasone administration. Enzyme linked immune assays were used to measure circulating inflammatory cytokines and anti-angiogenic factors. Repeated measures ANOVA was used to analyze the data collected before, after and during dexamethasone administration. RESULTS: 17 women with HELLP syndrome were enrolled in this study. Dexamethasone significantly decreased evidence of hemolysis (p=0.002) and liver enzymes (p=0.003), while significantly increasing platelets (p=0.0001) within 24hrs of administration. Circulating IL-6 levels after 24hrs were decreased (p<0.001); sFlt-1 and sEndoglin were also significantly decreased by 24hrs post dexamethasone administration (p<0.002, p<0.004). There were no significant differences in circulating levels of PlGF (p=0.886) due to dexamethasone administration. AT1- autoantibody levels were unchanged by dexamethasone administration. CONCLUSION: We conclude that one important mechanism of dexamethasone administration is to blunt the release of both anti-angiogenic and inflammatory factors suggested to play role in the pathophysiology of HELLP syndrome.
    American journal of obstetrics and gynecology 02/2013; 208(5). DOI:10.1016/j.ajog.2013.01.049 · 4.70 Impact Factor
Show more